8-K current report · filed Oct 28, 2026

D-Wave Quantum Inc. (QBTS) 8-K Current Report: October 28, 2026

Item EX-99.2Item EX-99.1Item 7.01QBTS overview

Short answer

D-Wave Quantum Inc. (QBTS) filed an 8-K current report with the SEC on October 28, 2026 reporting Item EX-99.2 (Exhibit EX-99.2), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Non-binding MOU with LG CNS targeting enterprise optimization adoption in South Korea and international markets.

D-Wave Quantum Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Non-binding MOU with LG CNS targeting enterprise optimization adoption in South Korea and international markets
  • Joint efforts combine D-Wave annealing technology with LG CNS integration and optimization expertise
  • Target industries: manufacturing, telecommunications, finance and retail, with potential joint go-to-market activity
  • Shionogi quantum-assisted model produced 97% chemically valid molecules versus 73% for a classical model
  • ¥40 million NEDO prize funds Shionogi’s continued quantum computing research in drug candidate design

Item EX-99.1 · Exhibit EX-99.1

  • Non-binding MOU with LG CNS, a major South Korean AI transformation and systems-integration company
  • Strategic focus: commercialize D-Wave annealing quantum optimization across manufacturing, telecom, finance and retail
  • Joint efforts target moving enterprise applications from proof of concept into production and pursuing go-to-market opportunities
  • Potential expansion of D-Wave’s customer pipeline in South Korea and international markets, without disclosed revenue commitments
  • Near-term financial impact remains uncertain because the agreement is non-binding and contains no disclosed transaction value

Item EX-99.2 · Exhibit EX-99.2

  • Shionogi won first place in NEDO’s Quality of Life category for quantum-assisted drug discovery research
  • ¥40 million prize funds continued Shionogi research using D-Wave annealing technology and classical computing
  • Quantum-assisted model produced 97% chemically valid molecules versus 73% for the equivalent classical model
  • Results strengthen D-Wave’s commercial drug-discovery use case, but do not indicate immediate revenue impact for QBTS

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other D-Wave Quantum Inc. 8-K filings

Get the next QBTS 8-K as it lands

Follow QBTS for push alerts, or ask the research agent what this filing means.